中华肿瘤杂志
中華腫瘤雜誌
중화종류잡지
CHINESE JOURNAL OF ONCOLOGY
2015年
4期
266-271
,共6页
小细胞肺癌%抗药性,肿瘤%预后%RLIP76
小細胞肺癌%抗藥性,腫瘤%預後%RLIP76
소세포폐암%항약성,종류%예후%RLIP76
Small cell lung carcinoma%Drug resistance,neoplasm%Prognosis%RLIP76
目的：探讨RLIP76在调节小细胞肺癌多药耐药中的作用，并分析其表达与患者预后的关系。方法采用实时荧光定量PCR法和Western blot检测小细胞肺癌敏感细胞株H69和耐药细胞株H69AR中RLIP76的表达，应用小干扰RNA（siRNA）和 eGFP-RLIP76分别转染H69AR和H69细胞，采用CCK-8法检测细胞对化疗药物的敏感性，免疫组化法检测小细胞肺癌组织中RLIP76的表达，分析RLIP76与患者预后的关系。结果 H69AR 和H69细胞株中RLIP76的表达水平分别为13．675±0．983和1．074±0．107，差异有统计学意义（ P＜0．01）。通过siRNA下调H69AR中RLIP76的表达，能够增加细胞对化疗药物的敏感性，差异有统计学意义（ P＜0．001）。通过转染eGFP-RLIP76上调H69细胞中RLIP76的表达，细胞对化疗药物的敏感性降低，差异有统计学意义（ P＝0．003）。124例小细胞肺癌和64例癌旁组织中RLIP76的表达率分别为61．3％和9．4％，差异有统计学意义（ P＜0．01）。RLIP 76的表达与患者的临床分期、对化疗的敏感性和生存时间相关（均P＜0．05）。结论RLIP76参与调节小细胞肺癌的多药耐药，可作为评估小细胞肺癌化疗敏感性和临床预后的潜在靶基因。
目的：探討RLIP76在調節小細胞肺癌多藥耐藥中的作用，併分析其錶達與患者預後的關繫。方法採用實時熒光定量PCR法和Western blot檢測小細胞肺癌敏感細胞株H69和耐藥細胞株H69AR中RLIP76的錶達，應用小榦擾RNA（siRNA）和 eGFP-RLIP76分彆轉染H69AR和H69細胞，採用CCK-8法檢測細胞對化療藥物的敏感性，免疫組化法檢測小細胞肺癌組織中RLIP76的錶達，分析RLIP76與患者預後的關繫。結果 H69AR 和H69細胞株中RLIP76的錶達水平分彆為13．675±0．983和1．074±0．107，差異有統計學意義（ P＜0．01）。通過siRNA下調H69AR中RLIP76的錶達，能夠增加細胞對化療藥物的敏感性，差異有統計學意義（ P＜0．001）。通過轉染eGFP-RLIP76上調H69細胞中RLIP76的錶達，細胞對化療藥物的敏感性降低，差異有統計學意義（ P＝0．003）。124例小細胞肺癌和64例癌徬組織中RLIP76的錶達率分彆為61．3％和9．4％，差異有統計學意義（ P＜0．01）。RLIP 76的錶達與患者的臨床分期、對化療的敏感性和生存時間相關（均P＜0．05）。結論RLIP76參與調節小細胞肺癌的多藥耐藥，可作為評估小細胞肺癌化療敏感性和臨床預後的潛在靶基因。
목적：탐토RLIP76재조절소세포폐암다약내약중적작용，병분석기표체여환자예후적관계。방법채용실시형광정량PCR법화Western blot검측소세포폐암민감세포주H69화내약세포주H69AR중RLIP76적표체，응용소간우RNA（siRNA）화 eGFP-RLIP76분별전염H69AR화H69세포，채용CCK-8법검측세포대화료약물적민감성，면역조화법검측소세포폐암조직중RLIP76적표체，분석RLIP76여환자예후적관계。결과 H69AR 화H69세포주중RLIP76적표체수평분별위13．675±0．983화1．074±0．107，차이유통계학의의（ P＜0．01）。통과siRNA하조H69AR중RLIP76적표체，능구증가세포대화료약물적민감성，차이유통계학의의（ P＜0．001）。통과전염eGFP-RLIP76상조H69세포중RLIP76적표체，세포대화료약물적민감성강저，차이유통계학의의（ P＝0．003）。124례소세포폐암화64례암방조직중RLIP76적표체솔분별위61．3％화9．4％，차이유통계학의의（ P＜0．01）。RLIP 76적표체여환자적림상분기、대화료적민감성화생존시간상관（균P＜0．05）。결론RLIP76삼여조절소세포폐암적다약내약，가작위평고소세포폐암화료민감성화림상예후적잠재파기인。
Objective To investigate the role of RLIP76 in regulating multi-drug resistance in small cell lung cancer (SCLC), and to analyze the relationship between its expression and prognosis.Methods The expressions of RLIP 76 protein and gene were detected by Western blotting and real-time PCR ( RT-PCR) in both the chemosensitive SCLC H69 cell line and chemoresistant H69AR cell line, respectively.siRNA was transfected into the H69AR cells to inhibit RLIP76 expression, and eGFP-RLIP76 was transfected into the H69 cells to enhance RLIP76 expression.The drug-sensitivity of cells to chemotherapeutic drugs ( ADM, DDP, VP-16) were detected by CCK8 assay.The expression of RLIP76 in the SCLC tissues was detected by immunohistochemistry.The relationship of RLIP76 expression with clinicopathological features and prognosis of the patients was analyzed.Results The expression of RLIP76 in H69AR cells was 13.675 ±0.983, significantly higher than1 .074±0.107 in the H69 cells ( P<0.01) .The drug-sensitivities of H69AR cells to chemotherapeutic drugs were significantly increased when the expression of RLIP76 was down-regulated ( P<0.001) .The sensitivities of H69 cells to chemotherapeutic drugs ADM, DDP and VP-16 were significantly decreased after transfection with eGFP-RLIP76 up-regulating the RLIP76 expression ( P=0.003 ) .The positive expression rates were 61.3% and 9.4% in the SCLC tumor tissues and para-cancerous tissues, respectively ( P<0.01 ) .The expression of RLIP76 was significantly correlated with clinical stage, chemosensitivity and overall survival of the SCLC patients ( P<0.05) .Conclusions Our results suggest that RLIP76 is involved in the regulation of small cell lung cancer multidrug resistance.RLIP76 may serve as a potential target gene to evaluate the chemosensitivity and clinical prognostic for small cell lung cancer.
